Published in Neurology on June 14, 2005
Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®. Drugs R D (2010) 1.65
Clinical relevance of botulinum toxin immunogenicity. BioDrugs (2012) 1.64
Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics (2010) 1.33
Measuring the potency labelling of onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)) in an LD50 assay. J Neural Transm (Vienna) (2011) 1.12
A Phase III Study of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines. J Clin Aesthet Dermatol (2011) 1.08
Treatment of focal dystonias with botulinum neurotoxin. Toxicon (2008) 1.06
Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm (Vienna) (2010) 1.04
Botulinum toxin type A in the treatment of patients with cervical dystonia. Biologics (2009) 0.98
Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulinum toxin therapy. J Neural Transm (Vienna) (2012) 0.94
Prospective Study Evaluating IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm: Interim Results from the First 145 Subjects with Cervical Dystonia. Tremor Other Hyperkinet Mov (N Y) (2013) 0.94
Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. J Neurol (2015) 0.94
Comparing Botox and Xeomin for axillar hyperhidrosis. J Neural Transm (Vienna) (2010) 0.91
Treatment of dystonia. Neurotherapeutics (2014) 0.91
Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)). J Neural Transm (Vienna) (2013) 0.89
Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics (2014) 0.88
A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia. J Neural Transm (Vienna) (2013) 0.88
Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm. J Neural Transm (Vienna) (2013) 0.88
Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia. J Neurol Neurosurg Psychiatry (2013) 0.87
From poison to remedy: the chequered history of botulinum toxin. J Neural Transm (Vienna) (2007) 0.86
Botulinum toxin type A treatment to the upper face: retrospective analysis of daily practice. Clin Cosmet Investig Dermatol (2012) 0.85
Randomized, placebo-controlled trial of incobotulinumtoxina for upper-limb post-stroke spasticity. Muscle Nerve (2015) 0.85
'Similar to' is not 'identical with', and 'identical with' is not 'the same as'. Drugs R D (2015) 0.84
Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D (2015) 0.84
Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia. BMC Neurol (2014) 0.82
Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm. Clin Ophthalmol (2011) 0.82
Blepharospasm plus Cervical Dystonia with Predominant Anterocollis: A Distinctive Subphenotype of Segmental Craniocervical Dystonia? Tremor Other Hyperkinet Mov (N Y) (2011) 0.81
The treatment of cervical dystonia with botulinum toxins. J Neural Transm (Vienna) (2007) 0.80
A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins. Neuropsychiatr Dis Treat (2011) 0.80
A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia. J Neurol (2016) 0.80
Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke. J Neural Transm (Vienna) (2012) 0.79
Current and future medical treatment in primary dystonia. Ther Adv Neurol Disord (2012) 0.79
Diffusion of botulinum toxins. Tremor Other Hyperkinet Mov (N Y) (2012) 0.78
Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders. Drug Des Devel Ther (2015) 0.77
Patient considerations in the treatment of cervical dystonia: focus on botulinum toxin type A. Patient Prefer Adherence (2015) 0.77
Response to Commentary by W. Jost on: Pharmaceutical, Biological, and Clinical Properties of Botulinum Neurotoxin Type A Products. Drugs R D (2015) 0.76
Future aspects of botulinum neurotoxins. J Neural Transm (Vienna) (2007) 0.76
Botulinum Toxin Type A for the Treatment of Neuropathic Pain in Neuro-Rehabilitation. Toxins (Basel) (2015) 0.75
Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin. Front Neurol (2017) 0.75
Conversion Ratio between Botox(®), Dysport(®), and Xeomin(®) in Clinical Practice. Toxins (Basel) (2016) 0.75
Skin displacement analysis (SDA): a tool for the quantitative evaluation of skin movements elicited by underlying muscles in the face and neck area. Clin Cosmet Investig Dermatol (2011) 0.75
Considerations on patient-related outcomes with the use of botulinum toxins: is switching products safe? Ther Clin Risk Manag (2016) 0.75
Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm (Vienna) (2005) 1.97
EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. Eur J Neurol (2013) 1.52
Perianal thrombosis following injection therapy into the external anal sphincter using botulin toxin. Dis Colon Rectum (1995) 1.49
High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm (Vienna) (2004) 1.26
Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol (2013) 1.24
Use of botulinum toxin in anal fissure. Dis Colon Rectum (1993) 1.15
Driving in Parkinson's disease - a health hazard? J Neurol (2003) 1.00
Quantitative acoustic measurements for characterization of speech and voice disorders in early untreated Parkinson's disease. J Acoust Soc Am (2011) 0.99
Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. J Neural Transm (Vienna) (2004) 0.98
Evidence-based medicine: botulinum toxin A in migraine and tension-type headache. J Neurol (2001) 0.97
Changes of event related potential and cognitive processes in patients with subclinical hypothyroidism after thyroxine treatment. Endocr Regul (2002) 0.92
The assessment of beta amyloid, tau protein and cystatin C in the cerebrospinal fluid: laboratory markers of neurodegenerative diseases. Neurol Sci (2009) 0.90
[Botulinum toxin in specific pain therapy]. Schmerz (2003) 0.89
Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis. Pediatr Pulmonol (2001) 0.88
Gait analysis in patients with advanced Parkinson disease: different or additive effects on gait induced by levodopa and chronic STN stimulation. J Neural Transm (Vienna) (2005) 0.88
Eye movement in amyotrophic lateral sclerosis: a longitudinal study. Ger J Ophthalmol (1995) 0.87
[Non-motor Symptoms Questionnaire and Scale for Parkinson's disease. Cross-cultural adaptation into the German language]. Nervenarzt (2010) 0.86
Botulinum toxin in the treatment of neurological disorders of the autonomic nervous system. Arch Neurol (1999) 0.85
Treatment of drooling in Parkinson's disease with botulinum toxin. Mov Disord (1999) 0.83
[Disorders of eye movement in amyotrophic lateral sclerosis--report of 2 patients]. Klin Monbl Augenheilkd (1995) 0.83
Influence of age, gender, education and dexterity on upper limb motor performance in Parkinsonian patients and healthy controls. J Neural Transm (Vienna) (2003) 0.83
Interleukin-6 regulates the expression of hypothalamic neuropeptides involved in body weight in a gender-dependent way. J Neuroendocrinol (2011) 0.82
[Depression in Parkinson's disease. Part 1: epidemiology, signs and symptoms, pathophysiology and diagnosis]. Fortschr Neurol Psychiatr (2008) 0.81
Drug-induced impulse control disorders in Parkinson's disease. J Neurol (2011) 0.81
Interleukin-6 deletion in mice driven by aP2-Cre-ERT2 prevents against high-fat diet-induced gain weight and adiposity in female mice. Acta Physiol (Oxf) (2014) 0.80
Penile and perianal pudendal nerve somatosensory evoked potentials in the diagnosis of erectile dysfunction. Int J Impot Res (2001) 0.78
Autonomic disorders in multiple sclerosis. Autoimmune Dis (2011) 0.78
Penile sympathic skin response in erectile dysfunction. Eur Urol (1995) 0.78
[Diagnostic evaluation of the rectum and pelvic floor in chronic constipation]. Zentralbl Chir (1999) 0.78
Botulinum toxin in therapy of anal fissure. Lancet (1995) 0.77
EMG of the external anal sphincter: needle is superior to surface electrode. Dis Colon Rectum (2000) 0.77
[Gastrointestinal dysfunction in idiopathic Parkinson's disease]. Nervenarzt (2012) 0.77
Event-related potentials, CNV, readiness potential, and movement accompanying potential recorded from posterior thalamus in human subjects. A SEEG study. Neurophysiol Clin (2001) 0.77
Therapy of anal fissure using botulin toxin. Dis Colon Rectum (1994) 0.77
Equivalent doses of ropinirole and bromocriptine. Eur J Neurol (1999) 0.77
Current state of stem cell research for the treatment of Parkinson's disease. J Neurol (2002) 0.76
New laboratory markers in diagnosis of alzheimer dementia. Neurol Res (2009) 0.76
Use of botulinum toxin type A in management of adult spasticity. A European consensus statement. Eura Medicophys (2004) 0.76
Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients. Parkinsonism Relat Disord (2008) 0.76
[Prospective study of the direct and indirect costs of idiopathic Parkinson's disease]. Nervenarzt (2006) 0.76
Efficacy and tolerability of rasagiline in daily clinical use--a post-marketing observational study in patients with Parkinson's disease. Eur J Neurol (2010) 0.76
[Depression in Parkinson's disease--Part 2: Therapy and management]. Fortschr Neurol Psychiatr (2010) 0.76
Incidence of anal fissure in nonselected neurological patients. Dis Colon Rectum (1999) 0.75
[Blood pressure adaptation and hormone regulation in Parkinson patients following orthostasis]. Dtsch Med Wochenschr (1996) 0.75
[Bladder dysfunctions in encephalomyelitis disseminata--drug and interventional therapeutic options]. Fortschr Neurol Psychiatr (1995) 0.75
Intra- and interindividual reproducibility of heart rate variations in the tilt-table test. Wien Klin Wochenschr (2000) 0.75
[Stump formation and rehabilitation in amputations of the lower extremities]. Zentralbl Chir (1975) 0.75
Botulinum toxin type B in the treatment of anal fissures: first preliminary results. Dis Colon Rectum (2001) 0.75
Treatment of erectile dysfunction by an external ischiocavernous muscle stimulator. Eur Urol (1998) 0.75
[Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy]. Fortschr Neurol Psychiatr (2007) 0.75
Neurography of the pudendal nerve in pudendal canal syndrome. Dis Colon Rectum (1999) 0.75
Thrombolytic treatment of ischaemic stroke occurring during a migrainous attack: a case report. Cephalalgia (2010) 0.75
[Problem of indication for denervation surgery using Wilhelm's method in epicondylitis humeri radialis et ulnaris]. Beitr Orthop Traumatol (1975) 0.75
Riddle of the sphincters in anal fissure. Dis Colon Rectum (1995) 0.75
[Therapy of anal fissure using botulinum toxin: perianal thrombosis as a complication]. Dtsch Med Wochenschr (1995) 0.75
[Lambert-Eaton syndrome]. Med Klin (Munich) (1996) 0.75
[Projections in radiography of fractures]. Beitr Orthop Traumatol (1973) 0.75
Intrathecal antimeasles immunity in 140 patients with multiple sclerosis. Ann N Y Acad Sci (1988) 0.75
[Response to the letter by Dr.-H. Zermann on the contribution by W.H. Jost, "Value of electromyography in diagnosis of incontinence"]. Zentralbl Chir (1997) 0.75
East-west differences in the organization of botulinum toxin use in nine Central European countries. Eur J Neurol (2003) 0.75
[Patients' rights - medical duties (II). An analysis of the patients' rights law by physicians for physicians]. Versicherungsmedizin (2015) 0.75
[Analysis of direct costs in therapy of Parkinson disease]. Nervenarzt (2003) 0.75
[Dislocation of the head of the humerus in subcapital fractures]. Beitr Orthop Traumatol (1987) 0.75
[Help for patients with multiple sclerosis: current diagnostic and treatment possibilities in neurogenic disorders of bladder emptying]. Dtsch Med Wochenschr (1998) 0.75
Urethrismus accounting for voiding disorder. Urology (1998) 0.75
[Indirect costs in idiopathic Parkinson's disease]. Fortschr Neurol Psychiatr (2005) 0.75
[HELLP syndrome--amaurosis in sinus thrombosis with complete recovery]. Geburtshilfe Frauenheilkd (1994) 0.75
[Potential antinociceptive mechanisms of botulinum toxin]. Schmerz (2006) 0.75
[Iatrogenic injuries in stable osteosynthesis]. Beitr Orthop Traumatol (1982) 0.75
Evidence-based medicine (EBM). J Neurol (2001) 0.75
[When should we start medical treatment in Parkinson disease]. Fortschr Neurol Psychiatr (2010) 0.75
[Spiegelian hernia. Apropos of a series of 31 cases]. J Chir (Paris) (1992) 0.75
Is cardiovascular dysregulation in idiopathic Parkinson's syndrome correlated with decreased hormonal release?; TO THE EDITOR. Eur J Neurol (1997) 0.75
["Phantom gymnastics" of amputated limbs]. Beitr Orthop Traumatol (1979) 0.75
Influence of botulinum toxin injections on the sphincteric compound muscle action potential of the external anal sphincter. Dis Colon Rectum (1997) 0.75
Comparison of alpha-dihydroergocryptine and levodopa monotherapy in Parkinson's disease: assessment of changes in DAT binding with [123I]IPT SPECT. J Neural Transm (Vienna) (2004) 0.75